You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 10,143,723

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,143,723

Title:	Methods of using OX40 ligand encoding polynucleotides
Abstract:	The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.
Inventor(s):	Frederick; Joshua P. (Boston, MA), Bai; Ailin (Newton, MA)
Assignee:	ModernaTX, Inc. (Cambridge, MA)
Application Number:	15/996,140
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,143,723
Patent Claims:	1. A method for treating cancer in a subject by inducing or enhancing an anti-tumor immune response, comprising administering to the subject a messenger RNA (mRNA) encoding an OX40L polypeptide, wherein the mRNA comprises a 3' untranslated region (UTR) comprising at least one microRNA-122 (miR-122) binding site, thereby treating cancer in the subject by inducing or enhancing an anti-tumor immune response. 2. The method of claim 1, wherein the miR-122 binding site is a miR-122-3p binding site. 3. The method of claim 1, wherein the miR-122 binding site is a miR-122-5p binding site. 4. The method of claim 3, wherein the miR-122-5p binding site comprises the nucleotide sequence as set forth in SEQ ID NO: 26. 5. The method of claim 1, wherein the OX40L polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 1. 6. The method of claim 1, wherein the mRNA comprises an open reading frame, and wherein the open reading frame comprises a nucleotide sequence as set forth in SEQ ID NO: 4 or a nucleotide sequence at least 90% identical to SEQ ID NO: 4. 7. The method of claim 1, wherein the mRNA comprises a nucleotide sequence as set forth in SEQ ID NO: 65 or a nucleotide sequence at least 90% identical to SEQ ID NO: 65. 8. The method of claim 1, wherein the mRNA is chemically modified. 9. The method of claim 8, wherein the mRNA is fully modified with chemically-modified uridines. 10. The method of claim 9, wherein the chemically-modified uridines are N1-methylpseudouridines (m1.psi.). 11. The method of claim 8, wherein the mRNA is fully modified with 5-methylcytosine or is fully modified with N1-methylpseudouridines (m1.psi.) and 5-methylcytosine. 12. The method of claim 1, wherein the mRNA is formulated in a lipid nanoparticle. 13. The method of claim 12, wherein the lipid nanoparticle is administered intratumorally. 14. The method of claim 1, comprising administering an effective amount of a PD-1 antagonist, a PD-L1 antagonist or a CTLA-4 antagonist. 15. The method of claim 14, wherein the PD-1 antagonist is an antibody or antigen binding portion thereof that specifically binds to PD-1, wherein the PD-L1 antagonist is an antibody or antigen binding portion thereof that specifically binds to PD-L1, and wherein the CTLA-4 antagonist is an antibody or antigen binding portion thereof that specifically binds to CTLA-4. 16. The method of claim 15, wherein the PD-1 antagonist is selected from the group consisting of nivolumab, pembrolizumab, and pidilizumab, wherein the PD-L1 antagonist is selected from the group consisting of durvalumab, avelumab, and atezolizumab, and wherein the CTLA-4 antagonist is selected from the group consisting of ipilimumab and tremelimumab. 17. The method of claim 1, wherein the anti-tumor immune response in the subject comprises T cell activation and wherein the T cell activation reduces or decreases the size of a tumor, or inhibits growth of a tumor, in the subject. 18. The method of claim 1, wherein the anti-tumor immune response in the subject comprises increasing the number of NK cells in the tumor microenvironment.

Details for Patent 10,143,723

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	YERVOY	ipilimumab	Injection	125377	March 25, 2011	⤷ Subscribe	2035-12-23
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	For Injection	125514	September 04, 2014	⤷ Subscribe	2035-12-23
Merck Sharp & Dohme Llc	KEYTRUDA	pembrolizumab	Injection	125514	January 15, 2015	⤷ Subscribe	2035-12-23
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	December 22, 2014	⤷ Subscribe	2035-12-23
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	October 04, 2017	⤷ Subscribe	2035-12-23
Bristol-myers Squibb Company	OPDIVO	nivolumab	Injection	125554	August 27, 2021	⤷ Subscribe	2035-12-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.